EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Low-dose ranibizumab in the treatment of AROP [aggressive retinopathy of prematurity]

Shreyangsi Biswas, Krishna P. Baidya

Kerala Journal of Ophthalmology · 2026-05 · 38 (2) · 167-173

DOI: 10.4103/kjo.kjo_30_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kerala Journal of Ophthalmology, online erschienen am 08.08.2026. Verfasst von Shreyangsi Biswas und 1 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Design

Hospital-based randomized clinical trial (academic trial).

Purpose

Efficacy of two Ranibizumab doses (0.125 mg/0.25 mg) in the treatment of aggressive retinopathy of prematurity (AROP).

Method

Seventy-four babies were randomized for low dose [LD] and conventional dose [CD] of intravitreal Ranibizumab for ZONE-1 AROP and ZONE-2 posterior AROP, and followed up over 6 months.

Results

Thirty-six AROP were allotted in LD [1 lost to F/U] and 35 in CD [1 lost to F/U and one died]. LD applied to 21 infant’s B/E and 15 infant’s S/E [total 57 eyes]. CD was given to 19 infants in B/E and 16 infants in S/E [total 54 eyes]. Both ZONE-1 AROP and ZONE-2 posterior AROP are present in the above two groups. In the CD, 50% of infants had recurrence of AROP, whereas the figure is only 28.07% in infants who were instilled with low-dose Ranibizumab. The rate of complete vascularization is significantly higher in the LD group, i.e., 56.14% in comparison to the CD group, where only 18.51% had complete vascularization. The rate of incomplete vascularization is also 1.6 times higher in the CD than in the LD group. Clinical Impact: Although the current consensus in India for treating AROP is a combination of LD or CD dose of anti-VEGF (vascular endothelial growth factor) with laser, LD anti-VEGF alone has proven more promising in terms of both complete vascularization and reduced recurrence rates. It is also cost-effective with a favorable risk-to-benefit ratio.

Zitieren

APA

Biswas, S., & Baidya, K. P. (2026). Low-dose ranibizumab in the treatment of AROP [aggressive retinopathy of prematurity]. Kerala Journal of Ophthalmology, 38(2), 167-173. https://doi.org/10.4103/kjo.kjo_30_26

Vancouver

Biswas S, Baidya KP. Low-dose ranibizumab in the treatment of AROP [aggressive retinopathy of prematurity]. Kerala Journal of Ophthalmology. 2026;38(2):167-173. doi:10.4103/kjo.kjo_30_26

BibTeX
@article{Biswas2026,
  author = {Biswas, Shreyangsi and Baidya, Krishna P.},
  title = {Low-dose ranibizumab in the treatment of AROP [aggressive retinopathy of prematurity]},
  journal = {Kerala Journal of Ophthalmology},
  year = {2026},
  volume = {38},
  number = {2},
  pages = {167--173},
  doi = {10.4103/kjo.kjo_30_26}
}
Kostenlos starten →